Interferon Beta-1a

Rebif is indicated for the treatment of relapsing multiple sclerosis. 1). 1).

AVONEXTM

Prefilled Syringe (PS) / AVONEXTM Prefilled Autoinjector (PEN) (interferon beta-1a) is indicated for:  Treatment of relapsing forms of multiple sclerosis (MS) o To slow the progression of disability o To decrease the frequency of clinical exacerbations o To reduce the number and volume of active brain lesions identified on Magnetic Resonance Imaging (MRI) scans.

 A subgroup of relapsing MS includes secondary progressive MS (SPMS) patients who are still experiencing relapses, also known as relapsing progressive MS (RPMS). In a study of patients with relapsing progressive MS, AVONEXTM showed an improvement on relapse rates and MRI measures in those patients who had greater disability at baseline.

 Treatment of people who have experienced a single demyelinating event, accompanied by abnormal MRI scans, with lesions typical of MS: o To delay the onset of clinically definite MS (as determined by a second demyelinating event).

AVONEX is indicated in adults for the treatment of • Patients diagnosed with relapsing multiple sclerosis (MS). In clinical trials, this was characterised by two or more acute exacerbations (relapses) in the previous three-years without evidence of continuous progression between relapses; AVONEX slows the progression of disability and decreases the frequency of relapses.

1). AVONEX should be discontinued in patients who develop progressive MS.